Please use this identifier to cite or link to this item:
Title: Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Issue Date: Dec-2017
Citation: Clin Transl Oncol.2017 Dec;(19)12:1454-1461
Abstract: To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer.
PMID: 28577152
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos

Files in This Item:
File Description SizeFormat 
PMC5700215.pdf878.42 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.